COMMENTARY

SGLT-2 Inhibitor Sales Would Plunge If Used Only in Younger, Obese Patients, but Cautious Administration Warranted

March 17, 2015
Drug makers have rolled out a flurry of sodium glucose co-transporter-2 (SGLT-2) inhibitors (six compounds/seven products) in Japan over a 10-month period, hoping to see them follow a successful class of dipeptidyl peptidase-4 (DPP-4) inhibitors. However, their sales performances have…

To read the full story

COMMENTARY

By Philip Carrigan

As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…

By Yoshinori Sagehashi

Debates on the planned FY2023 off-year drug price revision are now entering the final stretch. Healthcare providers and payers have made their conflicting positions clear on the scope of products to be covered by the re-pricing, while the pharma industry…

A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…

Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…